Sort   by:  
 Page size 
UnknownPhase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Not available
S-EPMC4053545 | biostudies-literature
UnknownPrognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Not available
S-EPMC9389637 | biostudies-literature
UnknownEnhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III.
Not available
S-EPMC12878629 | biostudies-literature
UnknownGemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Not available
S-EPMC6312010 | biostudies-literature
UnknownAdded prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Not available
S-EPMC7218423 | biostudies-literature
Sort   by:  
 Page size